Metraipolis › archive › dc_e64b2240c9db
Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF — Europe PMC PMID:35015787
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/35015787
- DOI
- 10.1371/journal.pone.0262479
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-31T15:29:20.192Z
- SHA-256 of the archived text
110d674dce1d07271e099ed5653bd232eceee2f53f31ed1a911348a2f6171c1d- Stable URL of this page
https://metraipolis.com/documento/dc_e64b2240c9db
How to cite
Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF — Europe PMC PMID:35015787 — Europe PMC (en), https://europepmc.org/article/MED/35015787 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_e64b2240c9db (Metraipolis archive dc_e64b2240c9db, sha256 110d674dce1d07271e099ed5653bd232eceee2f53f31ed1a911348a2f6171c1d)
BibTeX
@misc{dce64b2240c9db,
title = {Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF — Europe PMC PMID:35015787},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/35015787},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_e64b2240c9db; sha256 110d674dce1d07271e099ed5653bd232eceee2f53f31ed1a911348a2f6171c1d},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35015787. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Heart failure is a leading cause of hospitalizations and mortality worldwide. Heart failure with a preserved ejection fraction (HFpEF) represents a significant clinical challenge due to the lack of available treatment modalities for patients diagnosed with HFpEF. One symptom of HFpEF is impaired diastolic function that is associated with increases in left ventricular stiffness. Increases in myocardial fibrillar collagen content is one factor contributing to increases in myocardial stiffness. Cardiac fibroblasts are the primary cell type that produce fibrillar collagen in the heart. However, relatively little is known regarding phenotypic changes in cardiac fibroblasts in HFpEF myocardium. In the current study, cardiac fibroblasts were established from left ventricular epicardial biopsies obtained from patients undergoing cardiovascular interventions and divided into three categories: Referent control, hypertension without a heart failure designation (HTN (-) HFpEF), and hypertension with heart failure (HTN (+) HFpEF). Biopsies were evaluated for cardiac myocyte cross-sectional area (CSA) and collagen volume fraction. Primary fibroblast cultures were assessed for differences in proliferation and protein expression of collagen I, Membrane Type 1-Matrix Metalloproteinase (MT1-MMP), and α smooth muscle actin (αSMA). Biopsies from HTN (-) HFpEF and HTN (+) HFpEF exhibited increases in myocyte CSA over referent control although only HTN (+) HFpEF exhibited significant increases in fibrillar collagen content. No significant changes in proliferation or αSMA was detected in HTN (-) HFpEF or HTN (+) HFpEF cultures versus referent control. Significant increases in production of collagen I was detected in HF (-) HFpEF fibroblasts, whereas significant decreases in MT1-MMP levels were measured in HTN (+) HFpEF cells. We conclude that epicardial biopsies provide a viable source for primary fibroblast cultures and that phenotypic differences are demonstrated by HTN (-) HFpEF and HTN (+) HFpEF cells versus referent control. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-01-11). Identificativi: PMID 35015787 · PMCID PMC8752005 · DOI 10.1371/journal.pone.0262479. Pagina: https://europepmc.org/article/MED/35015787 — https://doi.org/10.1371/journal.pone.0262479. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-31T15:21:22.796Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.